A Phase 1 interventional study of Denosumab in Healthy Volunteer, sponsored by Amgen. Completed at 1 site in United States. Open to male participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-06.
Sponsored by Amgen · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase 1b, open-label, single dose study in healthy male subjects. Approximately 12 healthy male subjects will receive a subcutaneous injection of denosumab on Day 1. Subjects will be followed by a 105 day treatment-free follow-up period.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has provided ; Healthy male between ≥40 to ≤ 65 years of age (inclusive) at the time of enrollment; Subject must be willing and able to produce a semen sample on seven separate study visits; Subject must be willing to refrain from ejaculation for a 48 hour period prior to each sample collection;
Exclusion Criteria:
Any condition or drug therapy that might interfere with the subjects ability to ejaculate and produce a semen sample; abnormality during the screening physical examination, , or laboratory evaluation; Known history of blood in urine or semen; Osteonecrosis of the jaw (ONJ) or risk factors for ONJ such as invasive dental procedures (eg, tooth extraction, dental implants, oral surgery in the past 6 months), poor oral hygiene, periodontal and/or pre-existing dental disease; Recent tooth extraction (within 6 months of screening visit); Evidence of hypocalcemia at screening; Known vitamin D deficiency; (except non-melanoma skin cancers) within the last 5 years; Positive for (HIV) at screening or known diagnosis of AIDS; Positive Surface Antigen (HepBsAg) (indicative of chronic Hepatitis B) or detectable virus Ribonucleic acid (RNA) by Polymerase Chain Reaction (PCR) at screening (indicative of active Hepatitis C - screening is generally done by Hepatitis C Antibody (HepCAb), followed by Hepatitis C virus RNA by PCR if HepCAb is positive); History of or allergic reaction to mammalian cell derived drug products or sensitivity to any of the products or components to be administered during dosing; Known intolerance to calcium or vitamin D supplements; Subject previously has entered this study or has been previously exposed to denosumab in the past 12 months; Has donated or lost ≥ 400 mL of blood or plasma within 8 weeks prior to screening; Positive urine screen for alcohol and/or potential drugs of abuse at screening unless medication is prescribed by a physician and approved by the Investigator and Amgen; Known alcohol abuse or use of illicit drugs within 12 months of enrollment; Subject is unwilling or unable to limit alcohol consumption throughout the course of the study. Alcohol is prohibited 24 hours prior to screening and administration of product. Alcohol is limited to no more than 2 drinks per day for the duration of the study; where a standard drink is equivalent to 12 ounces of regular beer, 8-9 ounces of malt liquor, 5 ounces of wine, or 1.5 ounces of 80 proof distilled spirits; Currently receiving treatment in another investigational device or drug study, or less than 30 days or 5 half-lives (whichever is longer) since ending treatment on another investigational device or drug study(s). Other investigational procedures while participating in this study are excluded; Use of any non-Amgen approved over-the-counter or prescription medications, within the 14 days or 5 half-lives (whichever is longer), prior to receiving the dose of denosumab. Acetaminophen (up to 2 g per day) for analgesia and hormone replacement therapy (eg, androgen, thyroid) will be allowed. Other medications may be approved following review by the Principal Investigator and the Amgen Medical Monitor. Written documentation of this review and Amgen acknowledgement is required for subject participation; Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and Investigator's knowledge; Subject has any kind of disorder that, in the opinion of the Investigator, may compromise the ability of the subject to give written and/or to comply with all required study procedures; History or evidence of any other clinically significant disorder, condition or disease that, in the opinion of the Investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single subcutaneous injection
Biological: Denosumab
60 mg
Also known as: Prolia (R)
Maximum Observed Concentration (Cmax) of Denosumab in Seminal Fluid
Time frame: Days 1, 10, 22, 36, 50, 78 and 106
Time to Maximum Observed Concentration (Tmax) of Denosumab in Seminal Fluid
Time frame: Days 1, 10, 22, 36, 50, 78 and 106
Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Seminal Fluid
The area under the denosumab seminal fluid concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method.
Time frame: Days 1, 10, 22, 36, 50, 78 and 106
Maximum Observed Concentration (Cmax) of Denosumab in Serum
Time frame: Days 1, 10, 22, 36, 50, 78 and 106
Time to Maximum Observed Concentration (Tmax) of Denosumab in Serum
Time frame: Days 1, 10, 22, 36, 50, 78 and 106
Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Serum
The area under the denosumab serum concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method.
Time frame: Days 1, 10, 22, 36, 50, 78 and 106
Ratio of Maximum Seminal Fluid Concentration by the Serum Concentration (Cmax Ratio)
The ratio of maximum denosumab seminal fluid concentration over the denosumab serum concentration at the corresponding time point (Cmax Ratio)
Time frame: Days 1, 10, 22, 36, 50, 78 and 106
Ratio of Seminal Fluid AUC by Serum AUC for the 106 Day Dosing Period
The ratio of denosumab seminal fluid AUC over denosumab serum AUC for the 106-day dosing period.
Time frame: Days 1, 10, 22, 36, 50, 78 and 106
Ratio of Denosumab Seminal Fluid Concentration Over the Denosumab Serum Concentration at the Last Study Time Point (Day 106).
Time frame: Day 106
First patient enrolled 17 June 2013; last patient enrolled 17 June 2013.
| Milestone | Denosumab |
|---|---|
| Started | 12 |
| Completed | 12 |
| Not completed | 0 |
| ng/mL | Denosumab |
|---|---|
| Maximum Observed Concentration (Cmax) of Denosumab in Seminal Fluid | 100 ± 81.9 |
| days | Denosumab |
|---|---|
| Time to Maximum Observed Concentration (Tmax) of Denosumab in Seminal Fluid | 21 ± 81.9 |
The area under the denosumab seminal fluid concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method.
| days*ng/mL | Denosumab |
|---|---|
| Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Seminal Fluid | 5220 ± 4880 |
| ng/mL | Denosumab |
|---|---|
| Maximum Observed Concentration (Cmax) of Denosumab in Serum | 6170 ± 2070 |
| days | Denosumab |
|---|---|
| Time to Maximum Observed Concentration (Tmax) of Denosumab in Serum | 8.0 ± 81.9 |
The area under the denosumab serum concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method.
| days*ng/mL | Denosumab |
|---|---|
| Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Serum | 333000 ± 122000 |
The ratio of maximum denosumab seminal fluid concentration over the denosumab serum concentration at the corresponding time point (Cmax Ratio)
| ratio | Denosumab |
|---|---|
| Ratio of Maximum Seminal Fluid Concentration by the Serum Concentration (Cmax Ratio) | 0.0217 ± 0.0154 |
The ratio of denosumab seminal fluid AUC over denosumab serum AUC for the 106-day dosing period.
| ratio | Denosumab |
|---|---|
| Ratio of Seminal Fluid AUC by Serum AUC for the 106 Day Dosing Period | 0.0170 ± 0.0148 |
| ratio | Denosumab |
|---|---|
| Ratio of Denosumab Seminal Fluid Concentration Over the Denosumab Serum Concentration at the Last Study Time Point (Day 106). | 0.0197 ± 0.0318 |
Collected over 78 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denosumab 60 mg SC | — | 1/12 (8.3%) | 5/12 (41.7%) |
| Event | Denosumab 60 mg SC |
|---|---|
| Vertigo positionalEar and labyrinth disorders | 1/12 |
| Event | Denosumab 60 mg SC |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/12 |
| FallInjury, poisoning and procedural complications | 2/12 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 2/12 |
| Rectal haemorrhageGastrointestinal disorders | 1/12 |
| FatigueGeneral disorders | 1/12 |
| Diabetes mellitusMetabolism and nutrition disorders | 1/12 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 1/12 |
| HypophosphataemiaMetabolism and nutrition disorders | 1/12 |
| Age, Continuous(years) | Denosumab |
|---|---|
| Mean | 56.6 ± 7.0 |
| Sex: Female, Male(Participants) | Denosumab |
|---|---|
| Female | 0 |
| Male | 12 |
| Race/Ethnicity, Customized(participants) | Denosumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Black (or African American) | 0 |
| Mixed race | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| White | 11 |
| Othe | 1 |
| Body Mass Index (BMI)(kg/m^2) | Denosumab |
|---|---|
| Mean | 27.73 ± 4.21 |
The record gives a start of Jun 2013, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab